The initial goal is to determine if viral activation occurs following blood transfusion and if leukocyte depletion or irradiation can prevent it. Both clinical and laboratory data will be collected. Both CMV and HIV-1 will be studied in HIV-1 infected transfusion recipients. The initial part of the study will enroll 330 HIV-1 infected patients at the time they are scheduled for transfusion. The effects of gamma irradiation and leukocyte reduction on CMV and HIV viremia will be examined using quantitative PCR and viral culture. The effect of repeated transfusion, if needed, will also be assessed. Clinical data will be collected on transfused patients. The study will be a multicenter study of 330 HIV-1 infected patients with CD4 counts below 250 cell/cc3. Patients scheduled for transfusion will be entered into the study at the time of their first transfusion and randomized to one of three arms: to receive unmanipulated blood components, filtered blood, or irradiated blood. Patients will receive blood components treated in this way for a period of one to two years. Blood samples will be taken from the individuals before transfusion and at varying intervals after transfusion. These samples will be studied using the polymerase chain reaction technology and quantitative culture to determine if activation of CMV or HIV-1 occurs following transfusion. These tests will also be done at intervals when the patient is not being transfused to determine the values at baseline. These individuals will also be tested for a number of other immunological markers as determined by the steering committee. The individuals will also be examined by a physician regularly and monitored for the presence of opportunistic infection.

Agency
National Institute of Health (NIH)
Institute
Division of Blood Diseases And Resources (NHLBI)
Type
Research and Development Contracts (N01)
Project #
N01HB057126-011
Application #
6317908
Study Section
Project Start
1994-12-01
Project End
2000-06-30
Budget Start
2000-06-01
Budget End
2000-06-30
Support Year
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Blood Centers of the Pacific
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Asmuth, David M; Busch, Michael P; Laycock, Megan E et al. (2004) Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. Antiviral Res 63:123-31
Asmuth, David M; Kalish, Leslie A; Laycock, Megan E et al. (2003) Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. Transfusion 43:451-8
Murphy, Edward L; Grant, Robert M; Kropp, Jerry et al. (2003) Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. J Acquir Immune Defic Syndr 33:655-6
Roback, John D; Drew, W Lawrence; Laycock, Megan E et al. (2003) CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion 43:314-21
Lee, Tzong-Hae; Wen, Li; Chrebtow, Vera et al. (2002) Quantitation of residual WBCs in filtered blood components by high-throughput, real-time kinetic PCR. Transfusion 42:87-93
Roback, J D; Hillyer, C D; Drew, W L et al. (2001) Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion 41:1249-57
Eisenbud, R; Assmann, S F; Kalish, L A et al. (2001) Differences in difficulty adjudicating clinical events in patients with advanced HIV disease. J Acquir Immune Defic Syndr 28:43-6
Kruskall, M S; Lee, T H; Assmann, S F et al. (2001) Survival of transfused donor white blood cells in HIV-infected recipients. Blood 98:272-9
Yomtovian, R; Gernsheimer, T; Assmann, S F et al. (2001) WBC reduction in RBC concentrates by prestorage filtration: multicenter experience. Transfusion 41:1030-6
Collier, A C; Kalish, L A; Busch, M P et al. (2001) Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 285:1592-601

Showing the most recent 10 out of 14 publications